ASPI
VENTE TOTALE: 251 275 titres (~999 237,04 $ US)
- Insiders
- Mann Paul Elliot
- Total bought
- —
- Total sold
- $999,237
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-10
ASPI presents a deeply concerning financial profile with severe and persistent losses, negative ROE/ROIC, and an extraordinarily long cash conversion cycle of 840 days, making the business model fundamentally unviable…
The first sentence of the analysis written for ASPI on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 14.3% | 38.6% | 32.1% | 0.0% | 0.0% | |
| Ebit Margin | -666.6% | -773.5% | -3736.9% | 0.0% | 0.0% | |
| Ebitda Margin | -658.6% | -762.1% | -3728.2% | 0.0% | 0.0% | |
| Operating Profit Margin | -239.8% | -636.0% | -3704.6% | 0.0% | 0.0% | |
| Pretax Profit Margin | -669.0% | -779.7% | -3764.3% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -670.2% | -782.4% | -3762.9% | 0.0% | 0.0% | |
| Net Profit Margin | -734.2% | -780.3% | -3761.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -734.2% | -847.3% | -3761.0% | 0.0% | 0.0% | |
| Current Ratio | 12.177 | 9.314 | 1.852 | 1.705 | 10.619 | |
| Quick Ratio | 11.917 | 9.305 | 1.852 | 1.705 | 10.619 | |
| Solvency Ratio | -0.693 | -0.738 | -1.431 | -1.819 | -2.261 | |
| Cash Ratio | 8.734 | 8.768 | 1.394 | 1.234 | 9.737 | |
| Price To Earnings Ratio | -2.536 | -7.190 | -3.653 | -12.154 | -35.178 | |
| Price To Earnings Growth Ratio | -0.011 | -0.252 | -0.013 | -0.171 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.011 | -0.252 | -0.013 | -0.171 | 0.000 | |
| Price To Earnings Diluted Ratio | -2.536 | -7.190 | -3.653 | -12.154 | -35.178 | |
| Price To Earnings Diluted Growth Ratio | -0.011 | -0.252 | -0.013 | -0.171 | 0.000 | |
| Price To Book Ratio | 2.175 | 5.265 | 3.632 | 5.779 | 15.295 | |
| Price To Sales Ratio | 18.622 | 60.857 | 136.688 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.363 | -8.985 | -7.644 | -7.653 | -25.725 | |
| Price To Operating Cash Flow Ratio | -11.755 | -15.106 | -10.936 | -19.298 | -158.793 | |
| Debt To Assets Ratio | 0.421 | 0.400 | 0.071 | 0.066 | 0.130 | |
| Debt To Equity Ratio | 1.058 | 0.788 | 0.131 | 0.084 | 0.154 | |
| Debt To Capital Ratio | 0.514 | 0.441 | 0.116 | 0.077 | 0.134 | |
| Long Term Debt To Capital Ratio | 0.496 | 0.421 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.512 | 1.970 | 1.852 | 1.273 | 1.191 | |
| Working Capital Turnover Ratio | 0.112 | 0.130 | 0.140 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.155 | -2.365 | -0.954 | -1.518 | -1.904 | |
| Operating Cash Flow Sales Ratio | -1.584 | -4.029 | -12.499 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.256 | 1.681 | 1.431 | 2.522 | 6.173 | |
| Debt Service Coverage Ratio | -11.073 | -26.456 | -27.402 | -143.929 | -55.193 | |
| Interest Coverage Ratio | -99.463 | -101.805 | -135.322 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -2.771 | -17.778 | -11.506 | -86.840 | -12.318 | |
| Operating Cash Flow Coverage Ratio | -0.175 | -0.442 | -2.526 | -3.576 | -0.623 | |
| Capital Expenditure Coverage Ratio | -3.913 | -1.468 | -2.322 | -0.657 | -0.193 | |
| Dividend Paid And Capex Coverage Ratio | -3.913 | -0.000 | -2.322 | -0.657 | -0.193 | |
| Dividend Payout Ratio | 0.000 | -85,967.063 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.384 | -7.221 | -3.309 | -11.322 | -34.655 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 14.3% | ▼-24.3% | ▼-2.7% |
| Ebit Margin | -666.6% | ▲106.8% | ▲368.8% |
| Ebitda Margin | -658.6% | ▲103.5% | ▲371.2% |
| Operating Profit Margin | -239.8% | ▲396.1% | ▲676.3% |
| Pretax Profit Margin | -669.0% | ▲110.7% | ▲373.6% |
| Continuous Operations Profit Margin | -670.2% | ▲112.2% | ▲372.9% |
| Net Profit Margin | -734.2% | ▲46.1% | ▲320.9% |
| Bottom Line Profit Margin | -734.2% | ▲113.2% | ▲334.3% |
| Current Ratio | 12.177 | ▲2.862 | ▲5.043 |
| Quick Ratio | 11.917 | ▲2.612 | ▲4.837 |
| Solvency Ratio | -0.693 | ▲0.045 | ▲0.696 |
| Cash Ratio | 8.734 | ▼-0.035 | ▲2.760 |
| Price To Earnings Ratio | -2.535 | ▲4.655 | ▲9.607 |
| Price To Earnings Growth Ratio | -0.011 | ▲0.241 | ▲0.078 |
| Forward Price To Earnings Growth Ratio | -0.011 | ▲0.241 | ▲0.078 |
| Price To Earnings Diluted Ratio | -2.535 | ▲4.655 | ▲9.607 |
| Price To Earnings Diluted Growth Ratio | -0.011 | ▲0.241 | ▲0.078 |
| Price To Book Ratio | 2.175 | ▼-3.090 | ▼-4.254 |
| Price To Sales Ratio | 18.622 | ▼-42.235 | ▼-24.611 |
| Price To Free Cash Flow Ratio | -9.363 | ▼-0.378 | ▲2.511 |
| Price To Operating Cash Flow Ratio | -11.755 | ▲3.350 | ▲31.422 |
| Debt To Assets Ratio | 0.421 | ▲0.021 | ▲0.203 |
| Debt To Equity Ratio | 1.058 | ▲0.270 | ▲0.615 |
| Debt To Capital Ratio | 0.514 | ▲0.073 | ▲0.258 |
| Long Term Debt To Capital Ratio | 0.496 | ▲0.074 | ▲0.312 |
| Financial Leverage Ratio | 2.512 | ▲0.542 | ▲0.753 |
| Working Capital Turnover Ratio | 0.113 | ▼-0.018 | ▲0.036 |
| Operating Cash Flow Ratio | -1.155 | ▲1.210 | ▲0.424 |
| Operating Cash Flow Sales Ratio | -1.584 | ▲2.445 | ▲2.038 |
| Free Cash Flow Operating Cash Flow Ratio | 1.256 | ▼-0.426 | ▼-1.357 |
| Debt Service Coverage Ratio | -11.073 | ▲15.383 | ▲41.738 |
| Interest Coverage Ratio | -99.463 | ▲2.343 | ▼-32.145 |
| Short Term Operating Cash Flow Coverage Ratio | -2.771 | ▲15.007 | ▲23.472 |
| Operating Cash Flow Coverage Ratio | -0.175 | ▲0.267 | ▲1.294 |
| Capital Expenditure Coverage Ratio | -3.913 | ▼-2.445 | ▼-2.203 |
| Dividend Paid And Capex Coverage Ratio | -3.913 | ▼-3.913 | ▼-2.496 |
| Dividend Payout Ratio | 0.000 | ▲85967.062 | ▲17193.412 |
| Enterprise Value Multiple | -2.384 | ▲4.837 | ▲9.394 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $444.1M | $252.2M | $59.2M | $56.7M | $91.7M | |
| Enterprise value | $374.5M | $228.0M | $53.4M | $55.2M | $89.7M | |
| EV / Sales | 15.70x | 55.03x | 123.37x | 0.00x | 0.00x | |
| EV / Op. cash flow | -9.91x | -13.66x | -9.87x | -18.77x | -155.28x | |
| EV / Free cash flow | -7.90x | -8.12x | -6.90x | -7.44x | -25.16x | |
| EV / EBITDA | -2.38x | -7.22x | -3.31x | -11.32x | -34.66x | |
| Net debt / EBITDA | 0.44x | 0.76x | 0.36x | 0.32x | 0.78x | |
| Current ratio | 12.18x | 9.31x | 1.85x | 1.71x | 10.62x | |
| Income quality | 0.24x | 0.52x | 0.33x | 0.59x | 0.22x | |
| Graham net-net | $2 | $0 | -$0 | -$0 | $0 | |
| Tax burden | 109.7% | 100.1% | 99.9% | 100.0% | 100.0% | |
| Interest burden | 100.4% | 100.8% | 100.7% | 100.0% | 100.0% | |
| Working capital | $365.4M | $58.7M | $4.8M | $1.4M | $2.9M | |
| Invested capital | $410.5M | $85.3M | $20.1M | $10.4M | $6.8M | |
| Return on assets | -34.1% | -34.3% | -54.0% | -39.6% | -36.5% | |
| Operating ROA | -18.8% | -42.3% | -75.2% | -51.9% | 0.0% | |
| Return on tangible assets | -34.8% | -35.5% | -60.5% | -39.6% | -36.5% | |
| Return on equity | -85.8% | -67.5% | -99.9% | -50.4% | -43.5% | |
| Return on invested capital | -11.6% | -29.6% | -63.2% | -47.9% | -37.7% | |
| Return on capital employed | -11.9% | -30.2% | -65.4% | -48.3% | -38.1% | |
| Earnings yield | -39.4% | -12.8% | -27.5% | -8.7% | -2.8% | |
| Free cash flow yield | -10.7% | -11.1% | -13.1% | -13.1% | -3.9% | |
| Capex / Op. cash flow | -25.6% | -68.1% | -43.1% | -152.2% | -517.3% | |
| Capex / Depreciation | 504.9% | 0.0% | 6228.0% | 6163.9% | 15422.2% | |
| Capex / Sales | 40.5% | 274.4% | 538.4% | 0.0% | 0.0% | |
| SG&A / Sales | 202.3% | 598.8% | 3560.2% | 0.0% | 0.0% | |
| R&D / Sales | 51.8% | 75.7% | 176.6% | 0.0% | 0.0% | |
| Stock comp / Sales | 67.2% | 206.6% | 2019.2% | 0.0% | 0.0% | |
| Intangibles / Total assets | 2.0% | 3.4% | 10.8% | 0.0% | 0.0% | |
| Days sales outstanding | 791d | 65d | 791d | 0d | 0d | |
| Days payables outstanding | 103d | 146d | 1380d | 0d | 1124d | |
| Operating cycle | 943d | 74d | 791d | 0d | 0d | |
| Cash conversion cycle | 840d | -72d | -589d | 0d | -1124d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+76.1%EV / Sales ▼-71.5%EV / EBITDA ▲+67.0%EV / Op. cash flow ▲+3.746Earnings yield ▼-0.266
Profitability
Return on equity ▼-0.183Return on assets ▲+0.001Return on invested capital ▲+0.181Return on capital employed ▲+0.183Operating ROA ▲+0.235Income quality ▼-0.279Tax burden ▲+0.097
Efficiency
Days sales outstanding ▲+726.710Days payables outstanding ▼-43.739Operating cycle ▲+868.942Cash conversion cycle ▲+912.681Capex / Sales ▼-2.340R&D / Sales ▼-0.239
Balance-sheet strength
Current ratio ▲+2.863Net debt / EBITDA ▼-0.321Working capital ▲+306755610.000Invested capital ▲+325122998.000Intangibles / Total assets ▼-0.014
Change over 5 years
Valuation
Market cap ▲+384.1%EV / Sales n/aEV / EBITDA ▲+93.1%EV / Op. cash flow ▲+145.371Earnings yield ▼-0.366
Profitability
Return on equity ▼-0.423Return on assets ▲+0.024Return on invested capital ▲+0.261Return on capital employed ▲+0.262Operating ROA n/aIncome quality ▲+0.015Tax burden ▲+0.097
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-1021.470Operating cycle n/aCash conversion cycle ▲+1964.521Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.558Net debt / EBITDA ▼-0.340Working capital ▲+362523069.000Invested capital ▲+403613714.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-09 ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript
- 2026-09-08 ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for critical materials production, today hosts its inaugural Capital Markets Day in London. Management will outline the Company''s strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and will provide an overview of the building blocks supporting the Company''s long-term growth potential.
- 2026-09-01 BlackRock Inc. Purchases Shares of 9,217,198 ASP Isotopes Inc. $ASPI BlackRock Inc. acquired a new stake in shares of ASP Isotopes Inc. (NASDAQ: ASPI) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,217,198 shares of the company''s stock, valued at approximately $57,331,000. BlackRock Inc. owned about 6.01% of ASP Isotopes as of
- 2026-08-21 ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth ASP Isotopes NASDAQ: ASPI expects several of its business units to enter commercial production or expand output over the next six months, with Chief Executive Officer Paul Mann highlighting progress in helium, liquefied natural gas, stable isotopes and radiopharmaceuticals during a conference presentation.
- 2026-08-20 ASP Isotopes Inc. Announces that Renergen Limited''s Subsidiary has Commenced Commissioning of Liquid Helium Plant in South Africa Tetra4, a subsidiary of Renergen and the developer of the Virginia Gas Project, has started the commissioning phase of the Phase 1 Liquid Helium plant post engineering optimization The production is expected to be among the first new liquid helium supply to enter the market at a time of acute global shortage The Company remains on track to deliver liquid helium to customers during September and ramp production to nameplate capacity during 2H Following the successful start-up of Phase 1, the Company expects to advance to Phase 2 during 2H 2026. The Company is currently exploring ways to accelerate the revenues and cash flows from Phase 2 DALLAS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited (“Renergen”) and the developer of the Virginia Gas Project, has entered the commissioning phase of the Company''s liquid helium plant.
- 2026-08-19 Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.
- 2026-08-18 ASP Isotopes Announces Quantum Leap Energy is Evaluating Metal Conversion Opportunities in Namibia DALLAS, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“we,” "QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, is evaluating metal conversion opportunities in Namibia. As part of this evaluation, a public environmental and social impact assessment and consultation process has commenced for a proposed pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area of Namibia.
- 2026-08-17 ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , R.
- 2026-08-12 ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed ASP Isotopes NASDAQ: ASPI outlined plans to expand its isotope production, radiopharmacy and helium businesses during Canaccord Genuity''s 46th Annual Growth Conference, with commercial deliveries of several stable isotopes targeted for the second half of 2026.
- 2026-08-06 ASP Isotopes Inc. Announces that Renergen Limited''s Subsidiary has Entered into a Take-or-Pay Contract for the Supply of Liquified Natural Gas to Be Produced at the Virginia Gas Project in South Africa Tetra4, a subsidiary of Renergen and the developer of the Virginia Gas Project, has entered into an additional take-or-pay contract to supply liquified natural gas (LNG) to a domestic food processor, establishing a multi-year contracted cash flow supporting Phase 1 commercial operations, which remain targeted for completion in the third quarter of 2026